FDA Clearance for Echonous Vein Ultrasound

July 16, 2018  Source: The Verge 5,602

EchoNous announced that it has been granted FDA 510(k) clearance for its EchoNous Vein ultrasound device which could improve peripheral IV catheter placements. This system could provide real-time clear mages of superficial and deeper veins.

Nancy Moureau, the CEO from Picc Excellence said, “EchoNous Vein’s simple on-screen controls allow clinicians using ultrasound to clearly identify veins in the center of the display, helping to not just locate veins but to evaluate their health and quality prior to peripheral IV placement. As clinicians, we know that IV insertion selecting a healthy vein for catheter placement can help to reduce the chance of post-insertional complications. To have a tool specifically designed to easily select veins and guide catheter placement is extremely valuable as we’re always looking to improve the patient experience.”

EchoNous is planning to integrate the EchoNous Vein with the already existing Uscan intelligent medical tool to form the EchoNous platform and join the products under its Signostics brand of EchoNous moniker.

Kevin Goodwin, the CEO from EchoNous said, “Time is critical, especially when patients need an infusion or antibiotic treatment, and finding the right vein can be challenging. We designed the EchoNous Vein to provide nurses with rapid, clear images of veins to directly improve patient care, satisfaction and HCAHPS scores. We wanted to create an easy-to-use tool that would help to reduce failed sticks, as with each failure comes a much higher risk of vessel trauma or infections which can lead to longer stays in hospital and higher medical costs. The Signostics brand served as our entry point into the U.S. healthcare market, centered on the success of our AI-driven bladder volume measurement tool which combines machine learning with highly miniaturized ultrasound.”

By Ddu
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.